Clinical Trial Update: Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating outcomes of FlexHD versus Alloderm in breast reconstruction has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AlloDerm (acellular dermal matrix)
• FlexHD

Snippet

Sponsor: University of Arkansas | Conditions: Breast Neoplasm | Phase 4 | Status: WITHDRAWN